184 related articles for article (PubMed ID: 35789120)
1. Performance of Afirma genomic sequencing classifier and histopathological outcome are associated with patterns of atypia in Bethesda category III thyroid nodules.
Jin X; Lew M; Pantanowitz L; Smola B; Jing X
Cancer Cytopathol; 2022 Nov; 130(11):891-898. PubMed ID: 35789120
[TBL] [Abstract][Full Text] [Related]
2. Performance of Afirma genomic sequencing classifier and histopathological outcome in Bethesda category III thyroid nodules: Initial versus repeat fine-needle aspiration.
Jin X; Lew M; Pantanowitz L; Iyengar JJ; Haymart MR; Papaleontiou M; Broome D; Sandouk Z; Raja SS; Hughes DT; Smola B; Jing X
Diagn Cytopathol; 2023 Nov; 51(11):698-704. PubMed ID: 37519144
[TBL] [Abstract][Full Text] [Related]
3. Performance of Afirma genomic sequencing classifier vs gene expression classifier in Bethesda category III thyroid nodules: An institutional experience.
Zhang L; Smola B; Lew M; Pang J; Cantley R; Pantanowitz L; Heider A; Jing X
Diagn Cytopathol; 2021 Aug; 49(8):921-927. PubMed ID: 34021740
[TBL] [Abstract][Full Text] [Related]
4. Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes.
Baca SC; Wong KS; Strickland KC; Heller HT; Kim MI; Barletta JA; Cibas ES; Krane JF; Marqusee E; Angell TE
Cancer Cytopathol; 2017 May; 125(5):313-322. PubMed ID: 28152275
[TBL] [Abstract][Full Text] [Related]
5. Independent Comparison of the Afirma Genomic Sequencing Classifier and Gene Expression Classifier for Cytologically Indeterminate Thyroid Nodules.
Angell TE; Heller HT; Cibas ES; Barletta JA; Kim MI; Krane JF; Marqusee E
Thyroid; 2019 May; 29(5):650-656. PubMed ID: 30803388
[No Abstract] [Full Text] [Related]
6. Use of the Afirma Xpression Atlas for cytologically indeterminate, Afirma Genomic Sequencing Classifier suspicious thyroid nodules: Clinicopathologic analysis with postoperative molecular testing.
Munoz-Zuluaga CA; Heymann JJ; Solomon JP; Patel A; Siddiqui MT; Scognamiglio T; Gokozan HN
Am J Clin Pathol; 2024 May; 161(5):463-468. PubMed ID: 38104250
[TBL] [Abstract][Full Text] [Related]
7. Clinico-cytopathological subcategorization in thyroid nodules of atypia of undetermined significance/follicular lesion of undetermined significance using the TIRADS and Bethesda classifications.
Babajani A; Rahmani S; Raoufi M; Eidgahi ES; Dastjerdi AV; Behfarnia P; Khalili S; Moghaddam NA
Front Endocrinol (Lausanne); 2023; 14():1135196. PubMed ID: 37313444
[TBL] [Abstract][Full Text] [Related]
8. Probability of malignancy as determined by ThyroSeq v3 genomic classifier varies according to the subtype of atypia.
Gajzer DC; Tjendra Y; Kerr DA; Algashaamy K; Zuo Y; Menendez SG; Jorda M; Garcia-Buitrago M; Gomez-Fernandez C; Velez Torres JM
Cancer Cytopathol; 2022 Nov; 130(11):881-890. PubMed ID: 35775861
[TBL] [Abstract][Full Text] [Related]
9. Molecular testing results as a quality metric for evaluating cytopathologists' utilization of the atypia of undetermined significance category for thyroid nodule fine-needle aspirations.
VanderLaan PA; Nishino M
J Am Soc Cytopathol; 2022; 11(2):67-73. PubMed ID: 34756586
[TBL] [Abstract][Full Text] [Related]
10. An institutional experience: A retrospective analysis of the effect of transitioning from follicular lesion of undetermined significance to atypia of undetermined significance with subclassified atypia on interobserver concordance, rates of neoplasia, and rates of malignancy.
Kroll-Wheeler L; Cantley R; Pang JC; Soles BS; Smola B; Jing X; Lew M
Diagn Cytopathol; 2021 Jan; 49(1):31-38. PubMed ID: 32936526
[TBL] [Abstract][Full Text] [Related]
11. UTILITY OF ULTRASOUND VERSUS GENE EXPRESSION CLASSIFIER IN THYROID NODULES WITH ATYPIA OF UNDETERMINED SIGNIFICANCE.
Villabona CV; Mohan V; Arce KM; Diacovo J; Aggarwal A; Betancourt J; Amer H; Jose T; DeSantis P; Cabral J
Endocr Pract; 2016 Oct; 22(10):1199-1203. PubMed ID: 27409819
[TBL] [Abstract][Full Text] [Related]
12. Afirma Gene Sequencing Classifier Compared with Gene Expression Classifier in Indeterminate Thyroid Nodules.
Endo M; Nabhan F; Porter K; Roll K; Shirley LA; Azaryan I; Tonkovich D; Perlick J; Ryan LE; Khawaja R; Meng S; Phay JE; Ringel MD; Sipos JA
Thyroid; 2019 Aug; 29(8):1115-1124. PubMed ID: 31154940
[No Abstract] [Full Text] [Related]
13. Correlation Between Histological Diagnosis and Mutational Panel Testing of Thyroid Nodules: A Two-Year Institutional Experience.
Shrestha RT; Evasovich MR; Amin K; Radulescu A; Sanghvi TS; Nelson AC; Shahi M; Burmeister LA
Thyroid; 2016 Aug; 26(8):1068-76. PubMed ID: 27283257
[TBL] [Abstract][Full Text] [Related]
14. Different qualifiers of AUS/FLUS thyroid FNA have distinct BRAF, RAS, RET/PTC, and PAX8/PPARg alterations.
Bellevicine C; Sgariglia R; Migliatico I; Vigliar E; D'Anna M; Nacchio MA; Serra N; Malapelle U; Bongiovanni M; Troncone G
Cancer Cytopathol; 2018 May; 126(5):317-325. PubMed ID: 29469940
[TBL] [Abstract][Full Text] [Related]
15. Tumor Growth Rate Does Not Predict Malignancy in Surgically Resected Thyroid Nodules Classified as Bethesda Category III with Architectural Atypia.
Kim M; Jeon MJ; Han M; Lee JH; Song DE; Baek JH; Kim TY; Kim WB; Shong YK; Kim WG
Thyroid; 2019 Feb; 29(2):216-221. PubMed ID: 30421654
[TBL] [Abstract][Full Text] [Related]
16. Differences in risk of malignancy and management recommendations in subcategories of thyroid nodules with atypia of undetermined significance or follicular lesion of undetermined significance: the role of ultrasound-guided core-needle biopsy.
Choi YJ; Baek JH; Ha EJ; Lim HK; Lee JH; Kim JK; Song DE; Shong YK; Hong SJ
Thyroid; 2014 Mar; 24(3):494-501. PubMed ID: 23947771
[TBL] [Abstract][Full Text] [Related]
17. Combined molecular and histologic end points inform cancer risk estimates for thyroid nodules classified as atypia of undetermined significance.
Onken AM; VanderLaan PA; Hennessey JV; Hartzband P; Nishino M
Cancer Cytopathol; 2021 Dec; 129(12):947-955. PubMed ID: 34314102
[TBL] [Abstract][Full Text] [Related]
18. Thyroid nodules with atypia or follicular lesions of undetermined significance (Bethesda Category III): importance of ultrasonography and cytological subcategory.
Rosario PW
Thyroid; 2014 Jul; 24(7):1115-20. PubMed ID: 24684285
[TBL] [Abstract][Full Text] [Related]
19. Subclassification of the Bethesda Category III (AUS/FLUS): A study of thyroid FNA cytology based on ThinPrep slides from the National Cancer Center in China.
Zhao H; Guo H; Zhao L; Cao J; Sun Y; Wang C; Zhang Z
Cancer Cytopathol; 2021 Aug; 129(8):642-648. PubMed ID: 34139103
[TBL] [Abstract][Full Text] [Related]
20. Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS).
Ho AS; Sarti EE; Jain KS; Wang H; Nixon IJ; Shaha AR; Shah JP; Kraus DH; Ghossein R; Fish SA; Wong RJ; Lin O; Morris LG
Thyroid; 2014 May; 24(5):832-9. PubMed ID: 24341462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
